Last Price
2.26
Today's Change
+0.66 (41.25%)
Day's Change
1.91 - 2.67
Trading Volume
18,915,104
Exchange: NASDAQ Capital Market NASDAQ Capital Market
Currency: USD USD
Sector: Healthcare - Healthcare Healthcare - Healthcare
CEO: Mr. Paul Kang Mr. Paul Kang
Full Time Employees: 5 5
IPO Date: 2018-05-22 2018-05-22
CIK: 0001698530 0001698530
ISIN: US30205M2008 US30205M2008
CUSIP: 30205M101 30205M101
Beta: 1.24 1.24
Last Dividend: 0.00 0.00
Dcf Diff: 2.70 2.70
Dcf: -0.73 -0.73
Exicure, Inc., a biotechnology company, develops therapies for neurological disorders and hair loss based on its proprietary spherical nucleic acid (SNA) technology. Its lead program candidate includes SCN9A that is in preclinical studies for neuropathic and chronic pain. The company has a collaboration, option, and license agreement with AbbVie Inc. to develop SNA-based treatments for hair loss disorders; and collaboration agreement with Ipsen S.A. to research, develop, and commercialize novel spherical nucleic acids for Huntington's disease and Angelman syndrome. Exicure, Inc. was founded in 2011 and is headquartered in Chicago, Illinois.